Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01908101
Recruitment Status : Active, not recruiting
First Posted : July 25, 2013
Last Update Posted : November 12, 2018
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Washington

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : May 4, 2019
  Study Completion Date : No date given